Recently Viewed
Clear AllValue Research Rating
Quality Score 
0/0
Growth Score
0/0
Valuation Score
0/0
Momentum Score
0/0
Today’s Range
52 Week Range
Liquidity
Market cap
₹373 Cr
Revenue (TTM)
₹323 Cr
Net Profit (TTM)
₹10 Cr
ROE
4.4 %
ROCE
6.5 %
P/E Ratio
38.8
P/B Ratio
0.9
Industry P/E
26.59
EV/EBITDA
15.4
Div. Yield
0.8 %
Debt to Equity
0
Book Value
₹717
EPS
₹16.8
Face value
10
Shares outstanding
5,707,162
CFO
₹284.64 Cr
EBITDA
₹279.81 Cr
Net Profit
₹305.80 Cr
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Albert David
| -11.1 | -8.0 | -11.5 | -21.1 | 8.5 | 10.9 | -- |
|
BSE Healthcare
| -4.7 | -5.8 | -5.4 | 1.3 | 23.7 | 14.0 | 10.6 |
|
Company
|
2025
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
|---|---|---|---|---|---|---|---|
|
Albert David
| -45.0 | 37.2 | 72.1 | -6.3 | 34.1 | 6.9 | -1.5 |
|
BSE Small Cap
| -6.6 | 29.0 | 47.5 | -1.8 | 62.8 | 32.1 | -6.8 |
|
BSE Healthcare
| -3.3 | 43.1 | 37.0 | -12.1 | 20.9 | 61.4 | -3.5 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price (₹) | Market Cap (₹ Cr) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Albert David
|
654.6 | 372.8 | 322.6 | 9.6 | -3.4 | 2.4 | 38.8 | 0.9 |
| 2,791.2 | 34,920.1 | 5,201.6 | 1,014.6 | 22.9 | 25 | 34.4 | 7.6 | |
| 7,827.5 | 19,544.3 | 2,177.5 | 200.9 | 11.3 | 26.5 | 97.3 | 23.5 | |
| 1,565.8 | 11,917.5 | 2,089.5 | 622.0 | 31.3 | 20.4 | 19.4 | 3.6 | |
| 1,332.1 | 18,429.0 | 3,078.2 | 469.4 | 26.4 | 14.9 | 42.7 | 5.1 | |
| 1,961.1 | 31,410.1 | 4,193.0 | 753.8 | 22.7 | 20.8 | 41.7 | 7.8 | |
| 4,887.1 | 22,333.8 | 2,482.3 | 853.6 | 33.7 | 18.9 | 26.2 | 5.6 | |
| 4,778.6 | 7,918.9 | 1,348.5 | 293.5 | 28.1 | 50.7 | 27 | 11.4 | |
| 388.9 | 7,603.2 | 1,432.0 | 149.0 | 19.1 | 7.9 | 50.7 | 3.1 | |
| 971.2 | 8,938.5 | 4,725.6 | 528.7 | 14.9 | 20.7 | 17.5 | 3.0 |
No Review & Analysis are available.
Albert David Limited manufactures and trades in pharmaceutical formulations, infusion solutions, herbal dosage forms, and bulk drugs in India and internationally. It offers formulations for parenterals, oral/enterals, topical agents, aerosol,... gynecology therapy, orthopedic, and vision care products. Albert David Limited was incorporated in 1938 and is headquartered in Kolkata, India. Read more
Incorporated
1938
Chairman
Arun Kumar Kothari
Managing Director
--
Headquarters
Kolkata, West Bengal
Website
Our rating system has guided millions of investors in the past 20 years.
Annual Reports
The share price of Albert David Ltd is ₹654.60 (NSE) and ₹653.15 (BSE) as of 02-Apr-2026 IST. Albert David Ltd has given a return of 8.5% in the last 3 years.
The P/E ratio of Albert David Ltd is 38.79 times as on 02-Apr-2026, a 46 premium to its peers’ median range of 26.59 times.
The P/B ratio of Albert David Ltd is 0.91 times as on 02-Apr-2026, a 80 discount to its peers’ median range of 4.49 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2025
|
26.92
|
1.18
|
|
2024
|
8.14
|
1.60
|
|
2023
|
8.08
|
0.94
|
|
2022
|
8.61
|
1.09
|
|
2021
|
9.71
|
0.88
|
The 52-week high and low of Albert David Ltd are Rs 957.50 and Rs 579.90 as of 04-Apr-2026.
Albert David Ltd has a market capitalisation of ₹ 373 Cr as on 02-Apr-2026. As per SEBI classification, it is a Small Cap company.
Before investing in Albert David Ltd, assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
₹38.40
(
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.